TipHub

₹29.44

▲ +0.33 +1.13%

16 Sept 2026

BSE Listed

GSM · GSM 0
What does GSM · GSM 0 mean?
BSE · Graded Surveillance Measure (GSM 0)GSM targets fundamentally weak companies whose price doesn't square with their financials (tiny net worth or negative/extreme P/E). Practical meaning: the exchange doubts the price is backed by the business. Stage 0 is a watchlist; each higher stage makes the stock progressively harder to trade — tighter bands, full upfront margin, weekly-only trading, and at Stage IV no upward price movement at all. Exiting requires a quarterly review finding the criteria no longer met.Criteria: Shortlisted on objective financial parameters — net worth, net fixed assets, price-to-earnings multiple and market capitalisation. Stage 0 = base surveillance watchlist (identified under GSM, no graded price restriction yet); Stages I–VI add escalating curbs (price band, 100% margin, periodic call auction, settlement on a gross/trade-for-trade basis, no upward price movement).Exchange notice · 2026-06-25

Prism Medico & Pharmacy Ltd. (512217)

Volume: 4,018Avg Vol 1W: 5,027Avg Vol 1M: 6,29052W Range:₹15.51₹34.49
BSE www.prismmedico.in AI Report
Key Ratios
Checked 3h ago
Market Cap₹40 Cr
Current Price₹29.44
Previous Close₹29.11
High / Low (52w)₹34.49 / ₹15.51
Volume4,018
Avg Vol (1W)5,027
Avg Vol (1M)6,290
Stock P/E118.7
Book Value₹16.89
Dividend Yield0%
ROE206.6%
ROA-249.84%
Revenue (TTM)—
Revenue Growth—
Profit Margin-45.88%
Total Debt—
Shares Outstanding1 Cr
Face Value—
EPS (TTM)₹0
P/B1.74
Debt / Equity0.17
50 DMA₹28.75
200 DMA₹25.33
Day change+1.13%
SurveillanceGSM · GSM 0
Price Chart
₹29.44▲ 69.00% · 1Y
₹34₹158.4L
2025-09-16
2026-09-16

20-day avg volume: 6K shares

Pros
  • Healthy return on equity of 206.6%.
  • Company is almost debt-free.
Cons
  • Revenue fell 100% YoY.
  • Company is loss-making at the latest annual result.
  • Stock trades at a high P/E of 119.
Quarterly Results
MetricMar 2018Jun 2018Sept 2018Dec 2018Mar 2019Jun 2019Sept 2019Dec 2019
Revenue₹0 Cr₹6 Cr₹15 Cr₹17 Cr₹17 Cr₹9 Cr₹7 Cr₹10 Cr
EBITDA₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹-1 Cr₹0 Cr₹0 Cr₹0 Cr
Net Profit₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹-1 Cr₹0 Cr₹0 Cr₹0 Cr
EPS————————
Profit & Loss (Annual)
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹0 Cr₹0 Cr₹0 Cr₹2 Cr₹1 Cr₹0 Cr₹0 Cr₹0 Cr
EBITDA₹0 Cr₹0 Cr₹0 Cr₹1 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Net Profit₹0 Cr₹0 Cr₹0 Cr₹1 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
EPS————————
Balance Sheet
MetricMar 2017Mar 2018Mar 2019
Total Assets₹17 Cr₹16 Cr₹21 Cr
Total Liabilities₹4 Cr₹3 Cr₹8 Cr
Equity₹13 Cr₹13 Cr₹13 Cr
Total Debt———
Cash Flow
MetricMar 2018Mar 2019
Operating₹4 Cr₹0 Cr
Investing₹-3 Cr₹0 Cr
Financing₹-2 Cr₹-1 Cr
Free Cash Flow₹4 Cr₹0 Cr
Shareholding
Promoter 29.98% Institutions 0% Public 70.02%
Efficiency & Working Capital
ROCE2.8%
Interest Coverage2.2
Dividend Payout—
Debtor Days21 d
Inventory Days9 d
Payable Days39 d
Cash Conversion Cycle-8 d
Working Capital Days30 d
Shareholding Details

As of 2026-06-30

Promoter30%
FII0%
DII0%
Institutions0%
Public70%
Promoter Pledge0%
No. of Shareholders4,177
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodDec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026May 2026Jun 2026
Promoters25%25%25%25%25%25%25%25%25%25.5%30.2%30%
FIIs0%0%0%0%0%0%0%0%0%0%0%0%
DIIs0%0%0%0%0%0%0%0%0%0%0%0%
Public75%75%75%75%75%75%75%75%75%74.5%69.8%70%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders3,6503,7923,8664,1074,1784,3024,3064,3154,3064,2954,3004,177
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603————
Major Shareholders (>1%)
NameCategoryStakeShares
Dharmender KharbPublic Shareholding19.4%26,25,000
Symbiosis Pharmaceuticals Private LimitedShareholding of Promoter and Promoter Group15.7%21,23,083
Galaxy Vitacare Private LimitedShareholding of Promoter and Promoter Group13.3%17,97,672
Raju TyagiPublic Shareholding9.8%13,25,000
Sejal S NashatarPublic Shareholding2.5%3,40,000
Shilpa Harsh RupareliyaPublic Shareholding2.4%3,30,000
Harsh Jentibhai RupareliyaPublic Shareholding2.4%3,30,000
Anshul JajooPublic Shareholding1.4%1,90,150
Bosco Armando MenezesPublic Shareholding1.1%1,50,000
Emily Bosco MenezesPublic Shareholding1.1%1,50,000
Ramit WaliaShareholding of Promoter and Promoter Group1.1%1,45,106
Reeta DeviPublic Shareholding1%1,39,669
Board of Directors
NameDesignationYear
Sakshi LallerWhole-time Director2026
Davender SinghNon Executive Director2026
DINESH KUMARIndependent Non Exe. Director2026
Pradeep KumarIndependent Non Exe. Director2026
Sameer GuptaCompany Sec. & Compli. Officer2026
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹102566
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-12Board Meetings—
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2026000044
2026000011
2026000022
Substantial Acquisitions (SAST)

4 disclosure(s)

Market18/08/2021 · 22,165
Market12/08/2021 · 11,320
Market06/08/2021 · 25,000
Market26/07/2021 - 27/07/2021 · 65,000
Company Information
Incorporated2002
AuditorGarg Mendiratta and Associates
Investor Email[email protected]
🌐 www.prismmedico.in ↗

📍 D-118 Industrial Area, Phase VII, Mohali, Punjab, 160055

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Capricorn Systems Global Solutions Ltd.Vama Industries Ltd.Sunteck RealtyBentley Commercial Enterprises Ltd.Silver Oak Commercial Ltd.Classic Electricals Ltd.SPV Global Trading LimitedVeritas (India) Ltd.Jaybharat Textiles & Real Estate Ltd.Jai CorpNivi Trading Ltd.Ashirwad Capital Ltd.All “51” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search